Literature DB >> 17826682

The ongoing evolution of proteomics in malignancy.

Amit S Dhamoon1, Elise C Kohn, Nilofer S Azad.   

Abstract

The complementary fields of genomics and proteomics offer insights into the molecular mechanisms of diseases. While genomics seeks to define our genetic substrate, proteomics explores the structure and function of proteins, which are the end effectors of our genes. Proteomics has been revolutionized in the past decade by the application of techniques such as protein arrays, two-dimensional gel electrophoresis, and mass spectrometry. These techniques have tremendous potential for biomarker development, target validation, diagnosis, prognosis, and optimization of treatment in medical care, especially in the field of clinical oncology. We will discuss innovations in proteomic technologies and highlight their prospective applications to patient care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826682     DOI: 10.1016/j.drudis.2007.07.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

1.  Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Authors:  Paul B Romesser; David H Perlman; Douglas V Faller; Catherine E Costello; Mark E McComb; Gerald V Denis
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

2.  The proteome of normal pancreatic juice.

Authors:  Courtney J Doyle; Kyle Yancey; Henry A Pitt; Mu Wang; Kerry Bemis; Michele T Yip-Schneider; Stuart T Sherman; Keith D Lillemoe; Michael D Goggins; C Max Schmidt
Journal:  Pancreas       Date:  2012-03       Impact factor: 3.327

3.  From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia.

Authors:  Benedetta Apollonio; Maria Teresa Sabrina Bertilaccio; Umberto Restuccia; Pamela Ranghetti; Federica Barbaglio; Paolo Ghia; Federico Caligaris-Cappio; Cristina Scielzo
Journal:  J Vis Exp       Date:  2014-10-19       Impact factor: 1.355

Review 4.  Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways.

Authors:  A Herrmann; J Ooi; S Launay; J L Searcy; R F Deighton; J McCulloch; I R Whittle
Journal:  J Neurooncol       Date:  2011-01-11       Impact factor: 4.130

Review 5.  'Unknown' proteins and 'orphan' enzymes: the missing half of the engineering parts list--and how to find it.

Authors:  Andrew D Hanson; Anne Pribat; Jeffrey C Waller; Valérie de Crécy-Lagard
Journal:  Biochem J       Date:  2009-12-14       Impact factor: 3.857

Review 6.  Mass spectrometry based targeted protein quantification: methods and applications.

Authors:  Sheng Pan; Ruedi Aebersold; Ru Chen; John Rush; David R Goodlett; Martin W McIntosh; Jing Zhang; Teresa A Brentnall
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

Review 7.  Proteomics and syndrome of Chinese medicine.

Authors:  Chuan-Li Lu; Xiao-Ying Qv; Jian-Guo Jiang
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.